FBR Capital Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
February 25, 2016 7:00 AM ESTFourth quarter Auryxia net U.S. product sales of $4.8 million Keryx provides 2016 Auryxia net U.S. product sales guidance of $31 - $34 millionCompany on track to provide pivotal phase 3 data for iron deficiency anemia (IDA) in adults with pre-dialysis chronic kidney disease in early second quarter
BOSTON, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced its financial results for the fourth quarter and year ended December 31, 2015. The company also reviewed its... More
